{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:52:13Z","timestamp":1784307133004,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:00:00Z","timestamp":1696204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:00:00Z","timestamp":1696204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073535"],"award-info":[{"award-number":["82073535"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017962","name":"Jiangsu Commission of Health","doi-asserted-by":"publisher","award":["LKM2023037"],"award-info":[{"award-number":["LKM2023037"]}],"id":[{"id":"10.13039\/100017962","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nutr"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s00394-023-03253-2","type":"journal-article","created":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T03:08:57Z","timestamp":1696216137000},"page":"173-183","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Associations of dietary advanced glycation end products with liver steatosis via vibration controlled transient elastography in the United States: a nationwide cross-sectional study"],"prefix":"10.1007","volume":"63","author":[{"given":"Fangfei","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongxiao","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangyun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,2]]},"reference":[{"issue":"1","key":"3253_CR1","first-page":"20","volume":"11","author":"CI Andronescu","year":"2018","unstructured":"Andronescu CI, Purcarea MR, Babes PA (2018) Nonalcoholic fatty liver disease: epidemiology, pathogenesis and therapeutic implications. J Med Life 11(1):20\u201323","journal-title":"J Med Life"},{"issue":"1","key":"3253_CR2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/hep.29466","volume":"67","author":"C Estes","year":"2018","unstructured":"Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ (2018) Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 67(1):123\u2013133. https:\/\/doi.org\/10.1002\/hep.29466","journal-title":"Hepatology"},{"issue":"4","key":"3253_CR3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","volume":"18","author":"DQ Huang","year":"2021","unstructured":"Huang DQ, El-Serag HB, Loomba R (2021) Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 18(4):223\u2013238. https:\/\/doi.org\/10.1038\/s41575-020-00381-6","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"3253_CR4","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1111\/1541-4337.12593","volume":"19","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, Wang Y, Fu L (2020) Dietary advanced glycation end-products: perspectives linking food processing with health implications. Compr Rev Food Sci Food Saf 19(5):2559\u20132587. https:\/\/doi.org\/10.1111\/1541-4337.12593","journal-title":"Compr Rev Food Sci Food Saf"},{"issue":"11","key":"3253_CR5","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1080\/10408398.2020.1863904","volume":"62","author":"C Nie","year":"2022","unstructured":"Nie C, Li Y, Qian H, Ying H, Wang L (2022) Advanced glycation end products in food and their effects on intestinal tract. Crit Rev Food Sci Nutr 62(11):3103\u20133115. https:\/\/doi.org\/10.1080\/10408398.2020.1863904","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"7","key":"3253_CR6","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1007\/s00394-019-02129-8","volume":"59","author":"R Cordova","year":"2020","unstructured":"Cordova R, Knaze V, Viallon V, Rust P, Schalkwijk CG, Weiderpass E, Wagner KH, Mayen-Chacon AL, Aglago EK, Dahm CC, Overvad K, Tj\u00f8nneland A, Halkj\u00e6r J, Mancini FR, Boutron-Ruault MC, Fagherazzi G, Katzke V, K\u00fchn T, Schulze MB, Boeing H, Trichopoulou A, Karakatsani A, Thriskos P, Masala G, Krogh V, Panico S, Tumino R, Ricceri F, Spijkerman A, Boer J, Skeie G, Rylander C, Borch KB, Quir\u00f3s JR, Agudo A, Redondo-S\u00e1nchez D, Amiano P, G\u00f3mez-G\u00f3mez JH, Barricarte A, Ramne S, Sonestedt E, Johansson I, Esberg A, Tong T, Aune D, Tsilidis KK, Gunter MJ, Jenab M, Freisling H (2020) Dietary intake of advanced glycation end products (AGEs) and changes in body weight in European adults. Eur J Nutr 59(7):2893\u20132904. https:\/\/doi.org\/10.1007\/s00394-019-02129-8","journal-title":"Eur J Nutr"},{"issue":"2","key":"3253_CR7","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s40200-020-00614-0","volume":"19","author":"R Goudarzi","year":"2020","unstructured":"Goudarzi R, Sedaghat M, Hedayati M, Hekmatdoost A, Sohrab G (2020) Low advanced Glycation end product diet improves the central obesity, insulin resistance and inflammatory profiles in Iranian patients with metabolic syndrome: a randomized clinical trial. J Diabetes Metab Disord 19(2):1129\u20131138. https:\/\/doi.org\/10.1007\/s40200-020-00614-0","journal-title":"J Diabetes Metab Disord"},{"issue":"2","key":"3253_CR8","doi-asserted-by":"publisher","first-page":"685","DOI":"10.3892\/mmr.2019.10872","volume":"21","author":"J Wang","year":"2020","unstructured":"Wang J, Liu H, Xie G, Cai W, Xu J (2020) Identification of hub genes and key pathways of dietary advanced glycation end products-induced non-alcoholic fatty liver disease by bioinformatics analysis and animal experiments. Mol Med Rep 21(2):685\u2013694. https:\/\/doi.org\/10.3892\/mmr.2019.10872","journal-title":"Mol Med Rep"},{"issue":"35","key":"3253_CR9","doi-asserted-by":"publisher","first-page":"8026","DOI":"10.3748\/wjg.v22.i35.8026","volume":"22","author":"C Leung","year":"2016","unstructured":"Leung C, Herath CB, Jia Z, Andrikopoulos S, Brown BE, Davies MJ, Rivera LR, Furness JB, Forbes JM, Angus PW (2016) Dietary advanced glycation end-products aggravate non-alcoholic fatty liver disease. World J Gastroenterol 22(35):8026\u20138040. https:\/\/doi.org\/10.3748\/wjg.v22.i35.8026","journal-title":"World J Gastroenterol"},{"key":"3253_CR10","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.foodchem.2015.06.049","volume":"190","author":"J Scheijen","year":"2016","unstructured":"Scheijen J, Clevers E, Engelen L, Dagnelie PC, Brouns F, Stehouwer CDA, Schalkwijk CG (2016) Analysis of advanced glycation endproducts in selected food items by ultra-performance liquid chromatography tandem mass spectrometry: Presentation of a dietary AGE database. Food Chem 190:1145\u20131150. https:\/\/doi.org\/10.1016\/j.foodchem.2015.06.049","journal-title":"Food Chem"},{"issue":"7","key":"3253_CR11","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/apt.12459","volume":"38","author":"L Jiao","year":"2013","unstructured":"Jiao L, Kramer JR, Chen L, Rugge M, Parente P, Verstovsek G, Alsarraj A, El-Serag HB (2013) Dietary consumption of meat, fat, animal products and advanced glycation end-products and the risk of Barrett\u2019s oesophagus. Aliment Pharmacol Ther 38(7):817\u2013824. https:\/\/doi.org\/10.1111\/apt.12459","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"3253_CR12","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","volume":"156","author":"PJ Eddowes","year":"2019","unstructured":"Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, Guha IN, Cobbold JF, Deeks JJ, Paradis V, Bedossa P, Newsome PN (2019) Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing Steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 156(6):1717\u20131730. https:\/\/doi.org\/10.1053\/j.gastro.2019.01.042","journal-title":"Gastroenterology"},{"issue":"7","key":"3253_CR13","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1002\/hep4.1935","volume":"6","author":"M Noureddin","year":"2022","unstructured":"Noureddin M, Ntanios F, Malhotra D, Hoover K, Emir B, McLeod E, Alkhouri N (2022) Predicting NAFLD prevalence in the United states using National Health and Nutrition Examination Survey 2017\u20132018 transient elastography data and application of machine learning. Hepatol Commun 6(7):1537\u20131548. https:\/\/doi.org\/10.1002\/hep4.1935","journal-title":"Hepatol Commun"},{"issue":"11","key":"3253_CR14","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","volume":"37","author":"H Taheri","year":"2020","unstructured":"Taheri H, Malek M, Ismail-Beigi F, Zamani F, Sohrabi M, Reza Babaei M, Khamseh ME (2020) Effect of Empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind. Placebo-Controlled Trial Adv Therapy 37(11):4697\u20134708. https:\/\/doi.org\/10.1007\/s12325-020-01498-5","journal-title":"Placebo-Controlled Trial Adv Therapy"},{"issue":"1","key":"3253_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2337\/dc09-1227","volume":"33","author":"AP Carson","year":"2010","unstructured":"Carson AP, Reynolds K, Fonseca VA, Muntner P (2010) Comparison of A1C and fasting glucose criteria to diagnose diabetes among U.S adults. Diabetes care 33(1):95\u201397. https:\/\/doi.org\/10.2337\/dc09-1227","journal-title":"Diabetes care"},{"issue":"6","key":"3253_CR16","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr (2018) 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines. Hypertension 71(6):1269\u20131324. https:\/\/doi.org\/10.1161\/HYP.0000000000000066","journal-title":"Hypertension"},{"key":"3253_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.930224","volume":"13","author":"H Duan","year":"2022","unstructured":"Duan H, Zhang R, Chen X, Yu G, Song C, Jiang Y, He Y, Wan H, Shen J (2022) Associations of Uric acid with liver Steatosis and fibrosis applying vibration controlled transient elastography in the United States: a nationwide cross-section study. Front Endocrinol (Lausanne) 13:930224. https:\/\/doi.org\/10.3389\/fendo.2022.930224","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"3253_CR18","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1017\/S0007114520002871","volume":"125","author":"P Ghorbaninejad","year":"2021","unstructured":"Ghorbaninejad P, Djafarian K, Babaee N, Davarzani S, Ebaditabar M, Clark CCT, Shab-Bidar S (2021) A negative association of dietary advanced glycation end products with obesity and body composition in Iranian adults. Br J Nutr 125(4):471\u2013480. https:\/\/doi.org\/10.1017\/S0007114520002871","journal-title":"Br J Nutr"},{"issue":"2","key":"3253_CR19","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3109\/09637486.2015.1137889","volume":"67","author":"P Angoorani","year":"2016","unstructured":"Angoorani P, Ejtahed HS, Mirmiran P, Mirzaei S, Azizi F (2016) Dietary consumption of advanced glycation end products and risk of metabolic syndrome. Int J Food Sci Nutr 67(2):170\u2013176. https:\/\/doi.org\/10.3109\/09637486.2015.1137889","journal-title":"Int J Food Sci Nutr"},{"issue":"10","key":"3253_CR20","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1007\/s00125-016-4053-x","volume":"59","author":"H Vlassara","year":"2016","unstructured":"Vlassara H, Cai W, Tripp E, Pyzik R, Yee K, Goldberg L, Tansman L, Chen X, Mani V, Fayad ZA, Nadkarni GN, Striker GE, He JC, Uribarri J (2016) Oral AGE restriction ameliorates insulin resistance in obese individuals with the metabolic syndrome: a randomised controlled trial. Diabetologia 59(10):2181\u20132192. https:\/\/doi.org\/10.1007\/s00125-016-4053-x","journal-title":"Diabetologia"},{"issue":"7","key":"3253_CR21","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.2337\/dc11-0091","volume":"34","author":"J Uribarri","year":"2011","unstructured":"Uribarri J, Cai W, Ramdas M, Goodman S, Pyzik R, Chen X, Zhu L, Striker GE, Vlassara H (2011) Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes Care 34(7):1610\u20131616. https:\/\/doi.org\/10.2337\/dc11-0091","journal-title":"Diabetes Care"},{"issue":"3","key":"3253_CR22","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.jhep.2011.07.028","volume":"56","author":"KH Gaens","year":"2012","unstructured":"Gaens KH, Niessen PM, Rensen SS, Buurman WA, Greve JW, Driessen A, Wolfs MG, Hofker MH, Bloemen JG, Dejong CH, Stehouwer CD, Schalkwijk CG (2012) Endogenous formation of N\u03b5-(carboxymethyl)lysine is increased in fatty livers and induces inflammatory markers in an in vitro model of hepatic steatosis. J Hepatol 56(3):647\u2013655. https:\/\/doi.org\/10.1016\/j.jhep.2011.07.028","journal-title":"J Hepatol"},{"key":"3253_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/nu13103370","author":"K Litwinowicz","year":"2021","unstructured":"Litwinowicz K, Waszczuk E, Gamian A (2021) Advanced Glycation end-products in common non-infectious liver diseases: systematic review and meta-analysis. Nutrients. https:\/\/doi.org\/10.3390\/nu13103370","journal-title":"Nutrients"},{"issue":"6","key":"3253_CR24","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1161\/atvbaha.113.302281","volume":"34","author":"KH Gaens","year":"2014","unstructured":"Gaens KH, Goossens GH, Niessen PM, van Greevenbroek MM, van der Kallen CJ, Niessen HW, Rensen SS, Buurman WA, Greve JW, Blaak EE, van Zandvoort MA, Bierhaus A, Stehouwer CD, Schalkwijk CG (2014) N\u03b5-(carboxymethyl)lysine-receptor for advanced glycation end product axis is a key modulator of obesity-induced dysregulation of adipokine expression and insulin resistance. Arterioscler Thromb Vasc Biol 34(6):1199\u20131208. https:\/\/doi.org\/10.1161\/atvbaha.113.302281","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"3253_CR25","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1161\/atvbaha.115.306106","volume":"35","author":"KH Gaens","year":"2015","unstructured":"Gaens KH, Ferreira I, van de Waarenburg MP, van Greevenbroek MM, van der Kallen CJ, Dekker JM, Nijpels G, Rensen SS, Stehouwer CD, Schalkwijk CG (2015) Protein-bound plasma N\u03b5-(Carboxymethyl)lysine is inversely associated with central obesity and inflammation and significantly explain a part of the central Obesity-Related increase in inflammation: the hoorn and CODAM studies. Arterioscler Thromb Vasc Biol 35(12):2707\u20132713. https:\/\/doi.org\/10.1161\/atvbaha.115.306106","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"3253_CR26","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1097\/HJH.0000000000000460","volume":"33","author":"RD Semba","year":"2015","unstructured":"Semba RD, Sun K, Schwartz AV, Varadhan R, Harris TB, Satterfield S, Garcia M, Ferrucci L, Newman AB (2015) Serum carboxymethyl-lysine, an advanced glycation end product, is associated with arterial stiffness in older adults. Journal of hypertension 33(4):797\u2013803","journal-title":"Journal of hypertension"},{"key":"3253_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/nu11081748","author":"A Bettiga","year":"2019","unstructured":"Bettiga A, Fiorio F, Di Marco F, Trevisani F, Romani A, Porrini E, Salonia A, Montorsi F, Vago R (2019) The modern western diet rich in Advanced Glycation end-products (AGEs): an overview of its impact on obesity and early Progression of renal pathology. Nutrients. https:\/\/doi.org\/10.3390\/nu11081748","journal-title":"Nutrients"},{"issue":"10","key":"3253_CR28","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1093\/nutrit\/nuz034","volume":"77","author":"PVM Ribeiro","year":"2019","unstructured":"Ribeiro PVM, Tavares JF, Costa MAC, Mattar JB, Alfenas RCG (2019) Effect of reducing dietary advanced glycation end products on obesity-associated complications: a systematic review. Nutr Rev 77(10):725\u2013734. https:\/\/doi.org\/10.1093\/nutrit\/nuz034","journal-title":"Nutr Rev"},{"issue":"21","key":"3253_CR29","doi-asserted-by":"publisher","first-page":"11298","DOI":"10.1039\/d2fo01974d","volume":"13","author":"L Fan","year":"2022","unstructured":"Fan L, Yu W, Zhang B, Cao B, Wang M, Hu X (2022) Distinctive effects of different types of advanced glycation end-products (AGEs) on liver glucose metabolism. Food Funct 13(21):11298\u201311306. https:\/\/doi.org\/10.1039\/d2fo01974d","journal-title":"Food Funct"},{"issue":"15","key":"3253_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.202100321","volume":"65","author":"W Yu","year":"2021","unstructured":"Yu W, Fan L, Wang M, Cao B, Hu X (2021) Pterostilbene improves insulin resistance caused by advanced Glycation end products (AGEs) in hepatocytes and mice. Mol Nutr Food Res 65(15):e2100321. https:\/\/doi.org\/10.1002\/mnfr.202100321","journal-title":"Mol Nutr Food Res"},{"issue":"8","key":"3253_CR31","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","volume":"65","author":"E Buzzetti","year":"2016","unstructured":"Buzzetti E, Pinzani M, Tsochatzis EA (2016) The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 65(8):1038\u20131048. https:\/\/doi.org\/10.1016\/j.metabol.2015.12.012","journal-title":"Metabolism"},{"key":"3253_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20205037","author":"DH Fernando","year":"2019","unstructured":"Fernando DH, Forbes JM, Angus PW, Herath CB (2019) Development and progression of non-alcoholic fatty liver disease: the role of advanced Glycation end products. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms20205037","journal-title":"Int J Mol Sci"},{"key":"3253_CR33","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.metabol.2018.01.023","volume":"83","author":"SA Palma-Duran","year":"2018","unstructured":"Palma-Duran SA, Kontogianni MD, Vlassopoulos A, Zhao S, Margariti A, Georgoulis M, Papatheodoridis G, Combet E (2018) Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults. Metabolism 83:120\u2013127. https:\/\/doi.org\/10.1016\/j.metabol.2018.01.023","journal-title":"Metabolism"},{"issue":"3","key":"3253_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/micc.12603","volume":"27","author":"E Pereira","year":"2020","unstructured":"Pereira E, Silvares RR, Flores EEI, Rodrigues KL, Daliry A (2020) Pyridoxamine improves metabolic and microcirculatory complications associated with nonalcoholic fatty liver disease. Microcirculation 27(3):e12603. https:\/\/doi.org\/10.1111\/micc.12603","journal-title":"Microcirculation"}],"container-title":["European Journal of Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00394-023-03253-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00394-023-03253-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00394-023-03253-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T16:04:44Z","timestamp":1705680284000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00394-023-03253-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,2]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["3253"],"URL":"https:\/\/doi.org\/10.1007\/s00394-023-03253-2","relation":{},"ISSN":["1436-6207","1436-6215"],"issn-type":[{"value":"1436-6207","type":"print"},{"value":"1436-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,2]]},"assertion":[{"value":"12 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors in this paper do not have any possible conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All human studies have been approved by the National Centre for Health Statistics (NCHS) Research Ethics Review Board (Protocol #2018\u201301) and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. The studies involving human participants were reviewed and approved by National Center for Health Statistics Research Ethics Review Board (Protocol #2018\u201301). The patients\/participants provided their written informed consent to participate in our study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}